What Are the Fundamentals of Sotera Health Company (SHC)?

We're taking a closer look at Sotera Health Company today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 99.9% compared to -0.1% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

  • Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally.

  • Sotera Health Company has moved -61.6% over the last year compared to -17.4% for the S&P 500 -- a difference of -44.2%

  • SHC has an average analyst rating of hold and is 153.97% away from its mean target price of $6.8 per share

  • Its trailing 12 month earnings per share (EPS) is $0.43

  • Sotera Health Company has a trailing 12 month Price to Earnings (P/E) ratio of 40.2 while the S&P 500 average is 15.97

  • Its forward earnings per share (EPS) is $1.02 and its forward P/E ratio is 16.9

  • SHC has a Price to Earnings Growth (PEG) ratio of 0.5, which shows the company is very undervalued compared to its earnings growth estimates.

  • The company has a Price to Book (P/B) ratio of 8.0 in contrast to the S&P 500's average ratio of 2.95

  • Sotera Health Company is part of the Healthcare sector, which has an average P/E ratio of 13.21 and an average P/B of 4.07

  • Sotera Health Company has on average reported free cash flows of $112,748,333.30 over the last four years, during which time they have grown by an an average of 70.2%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.